260 related articles for article (PubMed ID: 30137552)
1. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.
Holroyd CR; Seth R; Bukhari M; Malaviya A; Holmes C; Curtis E; Chan C; Yusuf MA; Litwic A; Smolen S; Topliffe J; Bennett S; Humphreys J; Green M; Ledingham J
Rheumatology (Oxford); 2019 Feb; 58(2):e3-e42. PubMed ID: 30137552
[No Abstract] [Full Text] [Related]
2. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary.
Holroyd CR; Seth R; Bukhari M; Malaviya A; Holmes C; Curtis E; Chan C; Yusuf MA; Litwic A; Smolen S; Topliffe J; Bennett S; Humphreys J; Green M; Ledingham J
Rheumatology (Oxford); 2019 Feb; 58(2):220-226. PubMed ID: 30137623
[No Abstract] [Full Text] [Related]
3. [Safety of biologic therapy - results from the German biologics register RABBIT].
Strangfeld A; Zink A
Dtsch Med Wochenschr; 2014 Sep; 139(37):1817-20. PubMed ID: 25180996
[No Abstract] [Full Text] [Related]
4. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
[No Abstract] [Full Text] [Related]
5. The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
[No Abstract] [Full Text] [Related]
6. Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection.
Burton MJ; Curtis JR; Yang S; Chen L; Singh JA; Mikuls TR; Winthrop KL; Baddley JW
J Rheumatol; 2017 May; 44(5):565-570. PubMed ID: 28250142
[TBL] [Abstract][Full Text] [Related]
7. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
[TBL] [Abstract][Full Text] [Related]
8. [Infectious complications of biologic therapy in patients with rheumatoid arthritis].
Meyer-Olson D; Hoeper K; Schmidt RE
Z Rheumatol; 2010 Dec; 69(10):879-88. PubMed ID: 21128049
[TBL] [Abstract][Full Text] [Related]
9. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety.
Favalli EG; Caporali R; Sinigaglia L; Pipitone N; Miniati I; Montecucco C; Matucci-Cerinic M;
Clin Exp Rheumatol; 2011; 29(3 Suppl 66):S15-27. PubMed ID: 21906424
[TBL] [Abstract][Full Text] [Related]
11. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Rutherford AI; Patarata E; Subesinghe S; Hyrich KL; Galloway JB
Rheumatology (Oxford); 2018 Jun; 57(6):997-1001. PubMed ID: 29529307
[TBL] [Abstract][Full Text] [Related]
12. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
13. What do Australian patients with inflammatory arthritis value in treatment? A discrete choice experiment.
Ho KA; Acar M; Puig A; Hutas G; Fifer S
Clin Rheumatol; 2020 Apr; 39(4):1077-1089. PubMed ID: 31858340
[TBL] [Abstract][Full Text] [Related]
14. Preparing patients for biologic medications for dermatologic and rheumatic diseases.
Smith BJ; Nuccio BC; Graves KY; McMillan VM
JAAPA; 2018 Jun; 31(6):23-28. PubMed ID: 29762203
[TBL] [Abstract][Full Text] [Related]
15. How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers.
Chatzidionysiou K; Delcoigne B; Frisell T; Hetland ML; Glintborg B; Dreyer L; Cordtz R; Zobbe K; Nordström D; Trokovic N; Aaltonen K; Provan SA; Grondal G; Gudbjornsson B; Askling J
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32900882
[No Abstract] [Full Text] [Related]
16. [15 years experience with biological therapy of inflammatory rheumatic diseases in Czech national register ATTRA].
Pavelka K; Šedová L; Hejduk K; Dušek L
Cas Lek Cesk; 2016; 155(6):285-293. PubMed ID: 27917631
[TBL] [Abstract][Full Text] [Related]
17. [Rheumatoid arthritis: milestones in classification and treatment].
Fiehn C
Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
[TBL] [Abstract][Full Text] [Related]
18. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions.
Bays AM; Gardner G
Med Clin North Am; 2016 Jul; 100(4):719-31. PubMed ID: 27235612
[TBL] [Abstract][Full Text] [Related]
20. Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Bruce ES; Kearsley-Fleet L; Watson KD; Symmons DP; Hyrich KL
Rheumatology (Oxford); 2016 Jul; 55(7):1336-7. PubMed ID: 27118877
[No Abstract] [Full Text] [Related]
[Next] [New Search]
